ROHTO PHARMACEUTICAL CO.,LTD.
4527・Prime Market・Pharmaceuticals
Japan
Core segment of the domestic Health & Beauty Care business
| Period | Current | Previous | Change |
|---|---|---|---|
| Net Sales (External Customers) | ¥169,326 million | ¥164,988 million | ↑ |
| Segment Profit (Operating Profit) | ¥22,126 million | ¥22,453 million | ↓ |
| Segment Assets | ¥279,941 million | ¥255,255 million | ↑ |
| Depreciation and Amortization | ¥7,198 million | ¥6,659 million | ↑ |
| Increase in Tangible and Intangible Fixed Assets (Capital Expenditure) | ¥22,301 million | ¥8,479 million | ↑ |
| Goodwill Amortization | ¥320 million | ¥325 million | — |
Business Details
Comprises Rohto Pharmaceutical's core business together with domestic group companies such as Rohto Nitten Co., Ltd. and Tenshin Pharmaceutical Co., Ltd. Manufactures and sells Eye Care Related (Eye Drops, Eye Wash), Skin Care Related (Dermatological Drugs, Lip Balm, Functional Cosmetics), Oral & Food Related (Gastrointestinal Medicine, Kampo Medicine, Supplements), and Medical Related (CDMO Business, Prescription Ophthalmic Drugs, etc.) products. Aims to establish a leading position in the domestic OTC pharmaceutical market.
Recent Overview
Sales increased, but segment profit slightly declined due to lower earnings at consolidated subsidiaries
In FY2026 (ending March 2026), Japan segment net sales increased to ¥169,326 million (up 2.6% year on year). "Rohto V5," "Hada Labo," "Lip Balm," "GYUTTO," and "Eye Drops" performed well, and Rohto Nitten Co., Ltd. and Tenshin Pharmaceutical Co., Ltd. also contributed to sales growth. On the other hand, segment profit slightly declined to ¥22,126 million (down 1.5% year on year). While Rohto Pharmaceutical's core business maintained profit growth, lower earnings at consolidated subsidiaries had an impact. Capital expenditure (increase in tangible and intangible fixed assets) increased substantially to ¥22,301 million from ¥8,479 million in the previous fiscal year.
Key Products
Growth Drivers
- Expansion of OTC pharmaceutical and skin care product sales driven by increased inbound demand
- Strong performance of core and new products such as "Rohto V5," "Hada Labo," and "Lip Balm"
- Sales contribution from domestic group companies such as Rohto Nitten Co., Ltd. and Tenshin Pharmaceutical Co., Ltd.
- Expansion of the OTC pharmaceutical market driven by rising self-medication demand
- Expansion into new categories such as Hair Care ("GYUTTO")
- Development of Medical Related (CDMO business, prescription ophthalmic drugs) as a growth area
Risks
- Pressure on segment profit from rising cost ratios (higher raw material and materials prices)
- Lower profit margin due to increased selling, general and administrative expenses
- Sluggish domestic personal consumption due to continued consumer thrift-consciousness
- Risk that deteriorating performance at consolidated subsidiaries affects segment profit
- Impact on brand value and market share from intensifying price competition with competitors
Last updated: June 19, 2026